Methods. A retrospective cohort study was conducted of all patients at a VA medical center with a urine culture positive for vancomycin-resistant enterococci (VRE) and treated with ≥ 7 days of either linezolid or daptomycin between January 1 2007 and December 31 2012. Patients who received >24 hours of any agent active against VRE before initiation of either antibiotic, those with a urinary tract infection (UTI) in the previous year, those with more than 1 organism found on urine culture, patients on hemodialysis, and those with absolute neutrophil counts <500 cells/mm 3 were excluded.
The primary outcome was therapeutic failure, defined as a new urine culture positive for VRE within 1 month of completing initial antibiotic therapy. Secondary outcomes were a composite of treatment failure, which included a new urine culture positive for VRE, or the prescribing of any antibiotics for a UTI, or a urine analysis with >10 WBC/ hpf within 1 month of initial therapy completion.
Results. Twenty-nine patients met inclusion criteria; 21 were treated with linezolid and 8 with daptomycin. One patient treated with linezolid experienced therapeutic failure (4.76%) compared to no patients treated with daptomycin ( p > 0.05). Five patient (23.8%) treated with linezolid and 1 patient (12.5%) treated with daptomycin experienced the composite outcome treatment failure ( p = 0.50). A regression analysis for the variables of agent selected, presence of an indwelling catheter, or spinal cord injury or nursing home resident was completed; only spinal cord injury or nursing home resident was significant with an odds ratio of 11.0 (95% CI 1. 27-95.18; p = 0.025) . No patients in either group experienced significant adverse effects while receiving therapy.
Conclusion. In this small, retrospective cohort of patients with VRE UTIs there was no significant difference in outcomes between patients treated with linezolid or daptomycin. Patients with spinal cord injuries or who were nursing home residents had a higher risk of treatment failure.
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